Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Kyowa Kirin Co - Stock

Kyowa Kirin Co Stock

4151.T
JP3256000005
858523

Price

2,910.00
Today +/-
+0
Today %
+0 %
P

Kyowa Kirin Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kyowa Kirin Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kyowa Kirin Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kyowa Kirin Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kyowa Kirin Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kyowa Kirin Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kyowa Kirin Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kyowa Kirin Co’s growth potential.

Kyowa Kirin Co Revenue, EBIT and net profit per share

DateKyowa Kirin Co RevenueKyowa Kirin Co EBITKyowa Kirin Co Net Income
2026e525.39 B undefined0 undefined83.9 B undefined
2025e496.78 B undefined98.98 B undefined71.59 B undefined
2024e482.83 B undefined94.94 B undefined67.57 B undefined
2023442.23 B undefined93.85 B undefined81.19 B undefined
2022398.37 B undefined81.39 B undefined53.57 B undefined
2021352.25 B undefined60.85 B undefined52.35 B undefined
2020318.35 B undefined58.24 B undefined47.03 B undefined
2019305.82 B undefined54.06 B undefined67.08 B undefined
2018271.51 B undefined53.88 B undefined54.41 B undefined
2017353.38 B undefined62.5 B undefined42.9 B undefined
2016347.96 B undefined52.32 B undefined30.45 B undefined
2015364.32 B undefined43.77 B undefined29.77 B undefined
2014333.45 B undefined36.17 B undefined15.9 B undefined
2013340.61 B undefined51.77 B undefined30.08 B undefined
2012333.16 B undefined52.91 B undefined24.2 B undefined
2011343.72 B undefined46.14 B undefined25.61 B undefined
2010413.74 B undefined44.19 B undefined22.2 B undefined
2009309.11 B undefined24.95 B undefined8.8 B undefined
2008460.18 B undefined44.63 B undefined11.73 B undefined
2007392.12 B undefined39.4 B undefined23.48 B undefined
2006354.27 B undefined30.71 B undefined12.69 B undefined
2005353.44 B undefined25.54 B undefined16.22 B undefined
2004358.96 B undefined33.35 B undefined17.82 B undefined

Kyowa Kirin Co Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
341.54374.9882.99397.63397.36384.67374.91375.61378.67359.28348.84358.96353.44354.27392.12460.18309.11413.74343.72333.16340.61333.45364.32347.96353.38271.51305.82318.35352.25398.37442.23482.83496.78525.39
-9.79-77.87379.13-0.07-3.19-2.540.190.81-5.12-2.912.90-1.540.2410.6817.36-32.8333.85-16.92-3.072.24-2.109.26-4.491.56-23.1712.644.1010.6513.0911.019.182.895.76
38.3139.7938.1736.2236.2833.2433.8533.0633.9435.1437.1236.7935.9237.1036.9643.5345.2146.1657.4863.2462.4661.7561.8761.6763.4872.9873.9774.7375.0678.1874.85---
130.84149.1931.68144.01144.18127.86126.91124.16128.52126.27129.48132.07126.97131.43144.92200.3139.74190.98197.56210.69212.76205.9225.39214.59224.32198.15226.2237.91264.4311.46331.03000
28.6838.745.7829.7930.7423.4621.6617.7220.3616.0926.8433.3525.5430.7139.444.6324.9544.1946.1452.9151.7736.1743.7752.3262.553.8854.0658.2460.8581.3993.8594.9498.980
8.4010.336.977.497.746.105.784.725.384.487.699.297.238.6710.059.708.0710.6813.4215.8815.2010.8512.0115.0417.6919.8417.6818.2917.2720.4321.2219.6619.92-
10.6515.621.312.3413.546.1511.289.45.548.49.9217.8216.2212.6923.4811.738.822.225.6124.230.0815.929.7730.4542.954.4167.0847.0352.3553.5781.1967.5771.5983.9
-46.60-91.66847.209.69-54.5883.43-16.66-41.0651.5718.1679.61-8.97-21.7584.95-50.05-24.98152.3215.37-5.5024.29-47.1487.282.2740.8826.8423.28-29.9011.312.3451.55-16.775.9517.20
----------------------------------
----------------------------------
447447462457458442436436435434431428423405398574571570567549548548547.73547.73547.86547.98539.01537.48537.51537.57537.63000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Kyowa Kirin Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kyowa Kirin Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kyowa Kirin Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kyowa Kirin Co's financial health and stability.

Assets

Kyowa Kirin Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kyowa Kirin Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kyowa Kirin Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kyowa Kirin Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008null200920102011201220132014201520162017201820192020202120222023
22.5821.8712.4616.9915.3829.924.8723.5338.8230.9430.9420.6342.346.1845.0349.7727.2541.442.8855.8573.4444.4952.2660.0567.5797.25
19.3818.517.8214.7711.3610.579.7910.0114.3528.6428.6424.1832.1233.5532.9333.1736.7136.5623.7822.0322.2218.820.4719.518.4821.1
00000000000000000000000000
-6.7-8.08-22.14-13.72-1.58-8.64-13.16-10.25-14.53-23.06-23.06-23.48-6.75-33.93-24.03-24.51-32.43-13.02-12.42-20.65-25.54-18.35-37.796.9-52.6-11.53
-2.48-3.498.820.089.1-1.72-6.940.18-8.148.3248.322.87-3.48-5.175.21-1.55-12.151.5912.646.59-12.868.714.560.115.238.74
2.763.33.241.881.080.240.170.220.310.50.50.260.20.130.120.240.30.0600000000
9.5412.5112.2516.671.9412.4511.37.0112.2920.0420.0421.6913.6129.0615.9423.1816.8214.3518.3616.9214.1722.6828.6614.8422.568.61
32.7828.8116.9618.1134.2630.1114.5623.4630.5484.8384.8324.264.1840.6359.1356.8919.3866.5366.8863.8357.2653.6639.586.5548.67115.55
-22,500-17,327-11,830-12,783-9,202-7,264-9,001-13,040-14,401-18,230-18,230-19,777-35,472-17,489-26,926-34,725-34,652-20,096-30,097-22,334-20,142-21,257-35,227-19,766-28,666-32,852
23.42-1.998.382.5910.48-8.11-1.8-8.49-9.49-3.98-3.98-13.25-32.3718.46-98.77-77.1616.81-57.75-49.82-45.27-39.93-0.93252.56-11.36-17.19-20.38
45.9215.3420.2115.3719.68-0.847.214.554.9114.2514.256.533.135.95-71.85-42.4451.46-37.65-19.73-22.93-19.7920.32287.798.411.4812.47
00000000000000000000000000
-46,805-16,535-13,525-21,600-39,199-364-152443-8,974-12,087-12,087-585-5,380-6,585-47412-23,40552343-4,169-196-3,044-3,175-3,475-3,767-3,640
000-436-1,773-5,504-217-20,737-528-1,001-1,001-4,637-113-12,582-7,511-126-116-232000-22,601-14-23-11-10
-50,078-20,870-16,841-38,746-44,224-9,114-5,137-24,417-13,499-20,976-20,976-16,903-14,444-30,737-19,189-12,579-37,184-14,060-13,871-18,287-16,501-47,371-26,003-28,446-29,032-32,535
-11-6-65-13,460-9-13-13-18-18-201-201-309-383-137-175-15520-198-533-436-157-38817-7724142
-3,262-4,329-3,251-3,250-3,243-3,233-4,755-4,105-3,979-7,687-7,687-11,372-8,568-11,433-11,029-12,310-13,683-13,682-13,681-13,682-16,148-21,688-23,631-24,176-25,258-29,027
5.786.399.31-17.320.3212.918-9.217.5158.8558.85-5.9916.1427.68-57.22-31.09-2.23-4.230.291.611.184.9266.2648.074.1163.89
10,27611,4825,1255,32925,06122,8475,55510,42416,13766,60204,42528,71223,14232,20822,161-15,27446,43136,78441,49437,11332,3984,27566,78320,00782,699
00000000000000000000000000

Kyowa Kirin Co stock margins

The Kyowa Kirin Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kyowa Kirin Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kyowa Kirin Co.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kyowa Kirin Co's sales revenue. A higher gross margin percentage indicates that the Kyowa Kirin Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kyowa Kirin Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kyowa Kirin Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kyowa Kirin Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kyowa Kirin Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kyowa Kirin Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kyowa Kirin Co Margin History

Kyowa Kirin Co Gross marginKyowa Kirin Co Profit marginKyowa Kirin Co EBIT marginKyowa Kirin Co Profit margin
2026e74.85 %0 %15.97 %
2025e74.85 %19.92 %14.41 %
2024e74.85 %19.66 %13.99 %
202374.85 %21.22 %18.36 %
202278.18 %20.43 %13.45 %
202175.06 %17.27 %14.86 %
202074.73 %18.29 %14.77 %
201973.97 %17.68 %21.94 %
201872.98 %19.84 %20.04 %
201763.48 %17.69 %12.14 %
201661.67 %15.04 %8.75 %
201561.87 %12.01 %8.17 %
201461.75 %10.85 %4.77 %
201362.46 %15.2 %8.83 %
201263.24 %15.88 %7.26 %
201157.48 %13.42 %7.45 %
201046.16 %10.68 %5.36 %
200945.21 %8.07 %2.85 %
200843.53 %9.7 %2.55 %
200736.96 %10.05 %5.99 %
200637.1 %8.67 %3.58 %
200535.92 %7.23 %4.59 %
200436.79 %9.29 %4.96 %

Kyowa Kirin Co Stock Sales Revenue, EBIT, Earnings per Share

The Kyowa Kirin Co earnings per share therefore indicates how much revenue Kyowa Kirin Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kyowa Kirin Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kyowa Kirin Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kyowa Kirin Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kyowa Kirin Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kyowa Kirin Co Revenue, EBIT and net profit per share

DateKyowa Kirin Co Sales per ShareKyowa Kirin Co EBIT per shareKyowa Kirin Co Earnings per Share
2026e981.95 undefined0 undefined156.8 undefined
2025e928.48 undefined0 undefined133.8 undefined
2024e902.4 undefined0 undefined126.29 undefined
2023822.55 undefined174.55 undefined151.01 undefined
2022741.06 undefined151.41 undefined99.66 undefined
2021655.32 undefined113.2 undefined97.39 undefined
2020592.31 undefined108.35 undefined87.5 undefined
2019567.37 undefined100.29 undefined124.46 undefined
2018495.48 undefined98.33 undefined99.3 undefined
2017645.02 undefined114.08 undefined78.3 undefined
2016635.26 undefined95.52 undefined55.59 undefined
2015665.14 undefined79.9 undefined54.36 undefined
2014608.48 undefined66.01 undefined29.01 undefined
2013621.55 undefined94.48 undefined54.89 undefined
2012606.85 undefined96.37 undefined44.08 undefined
2011606.21 undefined81.38 undefined45.16 undefined
2010725.86 undefined77.52 undefined38.94 undefined
2009541.35 undefined43.69 undefined15.41 undefined
2008801.71 undefined77.75 undefined20.43 undefined
2007985.22 undefined98.99 undefined58.99 undefined
2006874.75 undefined75.81 undefined31.34 undefined
2005835.55 undefined60.38 undefined38.35 undefined
2004838.7 undefined77.92 undefined41.64 undefined

Kyowa Kirin Co business model

Kyowa Kirin Co Ltd is a Japanese pharmaceutical company that was founded over 70 years ago. The company is headquartered in Tokyo and has been listed on the stock exchange since 1974. It has over 6,000 employees worldwide and conducts research and development in the fields of bioscience and biotechnology. The history of Kyowa Kirin Co Ltd began in 1949 when the company was established as Kyowa Hakko Seiyaku Co Ltd. Initially, the company primarily focused on the production of pharmaceutical products and chemicals. In the 1990s, the company expanded globally and announced a focus on researching novel drugs. Today, Kyowa Kirin Co Ltd is a leading company in bioscience and biotechnology, offering a wide range of products and services. The company is divided into several business segments, including pharmaceuticals, biopharmaceuticals, and diagnostics. Kyowa Kirin Co Ltd has a comprehensive product range, from the asthma medication Nucala to the hearing loss medication Nouriast®. Nucala is an innovative medication for the treatment of severe asthma and was approved by the FDA in 2015. The medication has proven to be highly effective in clinical studies and has the potential to improve the lives of millions of people. Another important product from Kyowa Kirin Co Ltd is the cancer medication Mogamulizumab. The medication is used for the treatment of T-cell lymphomas, a rare form of lymph node cancer. Mogamulizumab was approved in Japan in 2012 and has since proven to be an effective medication in treating T-cell lymphomas. The company also conducts research and development in the field of regenerative medicine. An example of this is the medication Regsorin, which is used for the treatment of peripheral vascular diseases. Regsorin is a biologic made from the body's own fibronectin protein and is able to strengthen and repair blood vessels and capillaries. Another important business area for Kyowa Kirin Co Ltd is diagnostics. The company produces and distributes diagnostic tests for a range of diseases, including allergies, infectious diseases, and cancer. The diagnostics division of Kyowa Kirin Co Ltd works closely with the company's other business segments to develop and market innovative diagnostic tests. Overall, Kyowa Kirin Co Ltd is an outstanding example of a pharmaceutical company specializing in the research and development of novel drugs and therapies for serious diseases. The company has an impressive history of innovation over the decades and has established itself as a leading provider in biosciences and biotechnology. With its wide product range and innovative research efforts, Kyowa Kirin Co Ltd is a key player in the global market for medical therapies and diagnostics. Kyowa Kirin Co is one of the most popular companies on Eulerpool.com.

Kyowa Kirin Co SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Kyowa Kirin Co valuation based on historical P/E ratio, EBIT, and P/S ratio.

Kyowa Kirin Co shares outstanding

The number of shares was Kyowa Kirin Co in 2023 — This indicates how many shares 537.635 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kyowa Kirin Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kyowa Kirin Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kyowa Kirin Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kyowa Kirin Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kyowa Kirin Co Stock Dividend

In 2023, Kyowa Kirin Co paid a dividend amounting to 56 JPY. Dividend means that Kyowa Kirin Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Kyowa Kirin Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Kyowa Kirin Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Kyowa Kirin Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Kyowa Kirin Co Dividend History

DateKyowa Kirin Co Dividend
2026e57.98 undefined
2025e57.97 undefined
2024e57.99 undefined
202356 undefined
202251 undefined
202146 undefined
202044 undefined
201942 undefined
201835 undefined
201727 undefined
201625 undefined
201525 undefined
201425 undefined
201325 undefined
201220 undefined
201120 undefined
201020 undefined
200925 undefined
200815 undefined
200710 undefined
200615 undefined
200512.5 undefined
20047.5 undefined

Kyowa Kirin Co Stock Payout Ratio

In 2023, Kyowa Kirin Co had a payout ratio of 49.57%. The payout ratio indicates the percentage of the company's profits that Kyowa Kirin Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Kyowa Kirin Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Kyowa Kirin Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Kyowa Kirin Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Kyowa Kirin Co Payout Ratio History

DateKyowa Kirin Co Payout ratio
2026e49.64 %
2025e50.02 %
2024e49.33 %
202349.57 %
202251.18 %
202147.23 %
202050.29 %
201933.75 %
201835.25 %
201734.48 %
201644.97 %
201545.99 %
201486.15 %
201345.55 %
201245.38 %
201144.29 %
201051.36 %
2009162.34 %
200873.46 %
200716.95 %
200647.86 %
200532.59 %
200418.02 %
Unfortunately, there are currently no price targets and forecasts available for Kyowa Kirin Co.

Kyowa Kirin Co Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/202428.78 27.26  (-5.29 %)2024 Q1
12/31/202341.76 51.41  (23.1 %)2023 Q4
9/30/202346.81 59.35  (26.8 %)2023 Q3
6/30/202328.33 16.53  (-41.65 %)2023 Q2
3/31/202327.62 23.74  (-14.06 %)2023 Q1
12/31/202215.83 8.11  (-48.77 %)2022 Q4
9/30/202228.11 26.41  (-6.06 %)2022 Q3
6/30/202224.6 35.31  (43.55 %)2022 Q2
3/31/202224.17 29.85  (23.52 %)2022 Q1
12/31/202122.3 36.18  (62.24 %)2021 Q4
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Kyowa Kirin Co stock

Eulerpool World ESG Rating (EESG©)

93/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

81

Environment

Scope 1 - Direct Emissions
16,402
Scope 2 - Indirect emissions from purchased energy
21,897
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
38,299
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees32.097
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol✅
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kyowa Kirin Co Stock Shareholders

%
Name
Stocks
Change
Date
53.98 % Kirin Holdings Co Ltd288,819,000012/31/2023
3.16 % Nomura Asset Management Co., Ltd.16,883,765-78,2003/31/2024
1.55 % Nikko Asset Management Co., Ltd.8,287,24016,7003/31/2024
1.53 % MFS Investment Management8,193,267-49,9002/29/2024
1.51 % BlackRock Institutional Trust Company, N.A.8,104,28433,8003/31/2024
1.49 % Daiwa Asset Management Co., Ltd.7,984,693-27,8623/31/2024
1.42 % The Vanguard Group, Inc.7,598,126452,0003/31/2024
0.97 % SMBC Nikko Securities Inc.5,210,0001,115,00012/31/2023
0.96 % JPMorgan Securities Japan Co., Ltd.5,142,0001,501,00012/31/2023
0.79 % Norges Bank Investment Management (NBIM)4,229,689260,86612/31/2023
1
2
3
4
5
...
10

Kyowa Kirin Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Panion & BF Biotech - Stock
Panion & BF Biotech
SupplierCustomer0,63-0,42-0,33-0,73-0,47-0,56
Astellas Pharma - Stock
Astellas Pharma
SupplierCustomer0,600,05-0,03-0,52-0,180,43
Five Prime Therapeutics, Inc. - Stock
Five Prime Therapeutics, Inc.
SupplierCustomer0,550,63-0,53-0,73--
Otsuka Holdings - Stock
Otsuka Holdings
SupplierCustomer0,490,44-0,23-0,130,780,43
AVEO Pharmaceuticals - Stock
AVEO Pharmaceuticals
SupplierCustomer0,48-0,140,370,160,690,24
GlaxoSmithKline - Stock
GlaxoSmithKline
SupplierCustomer0,470,13-0,43-0,53-0,86-0,25
Kirin Holdings - Stock
Kirin Holdings
SupplierCustomer0,460,40-0,170,180,780,04
Chiome Bioscience - Stock
Chiome Bioscience
SupplierCustomer0,44-0,090,370,680,860,16
Royalty Pharma A - Stock
Royalty Pharma A
SupplierCustomer0,410,12-0,23-0,36-0,28-0,42
Excelsior Medical - Stock
Excelsior Medical
SupplierCustomer0,37-0,11-0,26-0,69-0,70-0,35
1
2
3
4
...
5

Kyowa Kirin Co stock: Frequently Asked Questions

What values and corporate philosophy does Kyowa Kirin Co represent?

Kyowa Kirin Co Ltd represents a set of core values and corporate philosophy. The company prioritizes the health and well-being of patients, aiming to contribute to the advancement of medical science and enhance the quality of life. Kyowa Kirin Co Ltd focuses on innovation, putting patient needs at the forefront of its research and development activities. The company believes in collaboration and partnerships to drive progress in delivering novel therapies and addressing unmet medical needs. With a commitment to integrity and ethical business practices, Kyowa Kirin Co Ltd strives to make a positive impact and improve the lives of patients worldwide.

In which countries and regions is Kyowa Kirin Co primarily present?

Kyowa Kirin Co Ltd is primarily present in Japan, where it is headquartered. Additionally, the company has a significant presence in other countries and regions worldwide. These include the United States, where it operates through a subsidiary, as well as various regions in Europe, including the United Kingdom, Germany, France, and Switzerland. With a global reach and a strong presence in multiple markets, Kyowa Kirin Co Ltd is able to leverage its expertise and product offerings across different regions to optimize its business operations and serve a diverse customer base effectively.

What significant milestones has the company Kyowa Kirin Co achieved?

Kyowa Kirin Co Ltd, a leading pharmaceutical company, has achieved noteworthy milestones over the years. Notably, the company successfully developed and launched several groundbreaking medicines, such as Poteligeo, a treatment for skin conditions like cutaneous T-cell lymphoma. Additionally, Kyowa Kirin Co Ltd secured regulatory approvals for novel therapies like CRYSVITA, a treatment for rare bone diseases. Furthermore, the company built strategic alliances and partnerships to expand its global footprint and enhance research capabilities. In recent years, Kyowa Kirin Co Ltd has shown a strong commitment to innovation and patient care, continuously striving to improve the lives of individuals worldwide through its breakthrough advancements.

What is the history and background of the company Kyowa Kirin Co?

Kyowa Kirin Co Ltd, formerly known as Kyowa Hakko Kirin Co Ltd, is a leading Japanese pharmaceutical company. Founded in 1949, it has a rich history and background in the healthcare sector. Kyowa Kirin specializes in the research, development, manufacturing, and marketing of innovative and life-saving pharmaceuticals. Over the years, the company has been dedicated to delivering high-quality medicines for a wide range of diseases, including cancer, renal diseases, and immune disorders. With a strong emphasis on scientific research and technological advancements, Kyowa Kirin has established itself as a trusted and reliable name in the global pharmaceutical industry.

Who are the main competitors of Kyowa Kirin Co in the market?

The main competitors of Kyowa Kirin Co Ltd in the market include other pharmaceutical and biotechnology companies such as Takeda Pharmaceutical Company Limited, Eisai Co Ltd, and Astellas Pharma Inc. These companies also operate in the healthcare sector, developing and selling various drugs and therapies. Kyowa Kirin Co Ltd competes with these companies in terms of research and development, product pipelines, market share, and global presence.

In which industries is Kyowa Kirin Co primarily active?

Kyowa Kirin Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Kyowa Kirin Co?

The business model of Kyowa Kirin Co Ltd is focused on the development, manufacturing, and commercialization of specialty pharmaceuticals. The company primarily operates in the fields of nephrology, oncology, and immunology. Kyowa Kirin Co Ltd strives to bring innovative and high-quality therapeutic solutions to patients worldwide. With a strong commitment to research and development, the company invests in advancements in biotechnology and strives to address unmet medical needs. Kyowa Kirin Co Ltd also collaborates with global partners to expand its product portfolio and reach a wider patient population, all while maintaining a strong focus on patient-centricity and improving healthcare outcomes.

What is the P/E ratio of Kyowa Kirin Co 2024?

The Kyowa Kirin Co P/E ratio is 23.15.

What is the P/S ratio of Kyowa Kirin Co 2024?

The Kyowa Kirin Co P/S ratio is 3.24.

What is the AlleAktien quality score of Kyowa Kirin Co?

The AlleAktien quality score for Kyowa Kirin Co is 7/10.

What is the revenue of Kyowa Kirin Co 2024?

The expected Kyowa Kirin Co revenue is 482.83 B JPY.

How high is the profit of Kyowa Kirin Co 2024?

The expected Kyowa Kirin Co profit is 67.57 B JPY.

What is the business model of Kyowa Kirin Co

Kyowa Kirin Co Ltd is a global pharmaceutical company based in Japan that focuses on the development, manufacturing, and marketing of medications for patients with rare diseases. The company's business operations are divided into four segments: 1. Pharmaceutical Business: Kyowa Kirin focuses on researching and developing innovative medications for patients with rare diseases or unmet medical needs. The portfolio includes treatments for diseases such as kidney diseases, cancer, blood disorders, immunological diseases, neurological diseases, and heart diseases. 2. Bio-Chemicals Business: Kyowa Kirin produces biochemical products for biotech companies and research institutions worldwide. The company is capable of manufacturing a wide range of biochemicals, enzymes, reagents, and active ingredients at the highest level. 3. Vaccines Business: Kyowa Kirin focuses on developing vaccines against life-threatening diseases in this segment. Kyowa Kirin's experts have decades of experience in vaccine development, significantly supporting the containment of infectious diseases. 4. Renal Diseases Business: The Renal Diseases Business segment provides innovative solutions for patients with kidney diseases. This target group includes particularly patients suffering from life-threatening chronic kidney diseases and in need of a kidney transplant. In this context, the product "Nesp" (Darbepoetin alfa) was developed to stimulate erythropoietin production, which promotes the formation of red blood cells. Kyowa Kirin Co Ltd is committed to improving lives and developing life-saving treatments for patients. The company employs a highly diversified business strategy. The aim is to increase the profitability of each business segment by combining the company's strengths in areas such as drug development, analysis and synthesis technology, clinical trials, production, and distribution. As a leading pharmaceutical company, Kyowa Kirin Co Ltd strives to continuously provide high-quality services to patients. To achieve this, the company collaborates closely with partners from the scientific and industrial sectors, as well as patient organizations worldwide. Kyowa Kirin also aims to act responsibly and integrate sustainable practices into all aspects of its business.

What is the Kyowa Kirin Co dividend?

Kyowa Kirin Co pays a dividend of 51 JPY distributed over payouts per year.

How often does Kyowa Kirin Co pay dividends?

The dividend cannot currently be calculated for Kyowa Kirin Co or the company does not pay out a dividend.

What is the Kyowa Kirin Co ISIN?

The ISIN of Kyowa Kirin Co is JP3256000005.

What is the Kyowa Kirin Co WKN?

The WKN of Kyowa Kirin Co is 858523.

What is the Kyowa Kirin Co ticker?

The ticker of Kyowa Kirin Co is 4151.T.

How much dividend does Kyowa Kirin Co pay?

Over the past 12 months, Kyowa Kirin Co paid a dividend of 56 JPY . This corresponds to a dividend yield of about 1.92 %. For the coming 12 months, Kyowa Kirin Co is expected to pay a dividend of 57.97 JPY.

What is the dividend yield of Kyowa Kirin Co?

The current dividend yield of Kyowa Kirin Co is 1.92 %.

When does Kyowa Kirin Co pay dividends?

Kyowa Kirin Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Kyowa Kirin Co?

Kyowa Kirin Co paid dividends every year for the past 23 years.

What is the dividend of Kyowa Kirin Co?

For the upcoming 12 months, dividends amounting to 57.97 JPY are expected. This corresponds to a dividend yield of 1.99 %.

In which sector is Kyowa Kirin Co located?

Kyowa Kirin Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kyowa Kirin Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kyowa Kirin Co from 3/1/2025 amounting to 29 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Kyowa Kirin Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Kyowa Kirin Co in the year 2023?

In the year 2023, Kyowa Kirin Co distributed 51 JPY as dividends.

In which currency does Kyowa Kirin Co pay out the dividend?

The dividends of Kyowa Kirin Co are distributed in JPY.

Other fundamentals and analyses of Kyowa Kirin Co in the deep dive.

Our stock analysis for Kyowa Kirin Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyowa Kirin Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.